Colchicine

證據等級: L5

預測適應症: 10 個

Colchicine: From Gout to Plasmodium falciparum Malaria

One-Sentence Summary

Colchicine is a long-established anti-inflammatory agent primarily used to treat acute gout attacks, Familial Mediterranean Fever (FMF), and recurrent pericarditis. The TxGNN model predicts it may be effective for Plasmodium falciparum malaria, with 0 clinical trials and 6 publications (all in vitro or basic science studies) currently supporting this direction. Evidence is limited to preclinical mechanistic data, placing this prediction at an early exploratory stage.

Quick Overview

Item	Content
Original Indication	Gout; autoinflammatory conditions (no Singapore regulatory data available — drug not registered)
Predicted New Indication	Plasmodium falciparum malaria
TxGNN Prediction Score	99.60%
Evidence Level	L4
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Colchicine's hallmark mechanism is binding to β-tubulin and inhibiting microtubule polymerisation. This disrupts cell division, neutrophil chemotaxis, and — through downstream effects on cytoskeletal scaffolding — NLRP3 inflammasome activation. Although DrugBank pharmacology data was not retrieved in this evidence pack, Colchicine's tubulin-targeting action is one of the most well-characterised small-molecule mechanisms in clinical pharmacology.

Plasmodium falciparum depends on a functional tubulin/microtubule system for intraerythrocytic cell division and gametocyte formation. Several in vitro studies from the late 1980s–1990s demonstrated that compounds binding to cytoskeletal proteins — including colcemid (a structural congener of Colchicine) and tubulozole isomers with colcemid-like effects on protein synthesis — inhibit P. falciparum growth in erythrocyte cultures. This body of work established parasite tubulin as a pharmacologically tractable target and provides indirect mechanistic support for the TxGNN prediction.

Critically, P. falciparum tubulins are structurally distinct from mammalian tubulins at the molecular level. This divergence may offer selectivity, but it also means Colchicine's affinity and potency against the parasite — and its therapeutic index in an in vivo malaria context — are entirely unknown. Colchicine carries a narrow therapeutic window in humans, and there are currently no clinical or animal model data to establish whether an effective antimalarial dose is safe. The TxGNN model likely identified this candidate based on pharmacological graph similarities, not direct experimental evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2670249	1989	In Vitro Study	Cell Biology International Reports	Nine tubulin-binding substances tested against intraerythrocytic P. falciparum; parasite tubulins appear molecularly distinct from mammalian tubulins; tubulozole-T showed promising selective antimalarial activity
2655935	1989	In Vitro Study	Cell Biology International Reports	Duplicate report of the same cytoskeletal compound screen; colchicine-class agents active in vitro with differential host vs. parasite selectivity noted
2221861	1990	In Vitro Study	Antimicrobial Agents and Chemotherapy	Tubulozole isomers (mechanism resembling colcemid) inhibit P. falciparum protein synthesis; colcemid itself shows analogous effect, providing indirect support for the colchicine-related mechanism
23505424	2013	In Vitro Study	PLoS ONE	Curcumin (a structurally distinct tubulin binder) disrupts P. falciparum microtubule architecture in vitro, further validating parasite tubulin as a druggable target
7511206	1994	In Vitro / Molecular	Molecular and Cellular Biology	pfmdr1-encoded Pgh1 expressed in mammalian cells increases chloroquine susceptibility; provides background context on P. falciparum drug resistance mechanisms relevant to any repurposing candidate
6362934	1984	Serological Study	Clinical and Experimental Immunology	Anti-intermediate filament antibodies detected in 82% of acute malaria patients; supports the concept that cytoskeletal disruption is a biologically significant feature of P. falciparum infection

Safety Considerations

Please refer to the package insert for safety information.

Note: Colchicine has a well-known narrow therapeutic window. Toxicity data (warnings, contraindications, drug–drug interactions) was not retrieved in this evidence pack. Before any research use in malaria settings, a full safety profile review — particularly regarding renal and hepatic dose adjustments, CYP3A4/P-gp interactions, and myelosuppression risk — is essential.

Conclusion and Next Steps

Decision: Research Question

Rationale: All supporting evidence is limited to in vitro and basic science studies from the 1980s–2010s; no clinical trials have been registered, and there are no animal model or pharmacokinetic data to define whether an effective antimalarial dose of Colchicine is achievable within its narrow therapeutic window. This indication cannot advance beyond hypothesis generation at this stage.

To proceed, the following is needed:

Retrieve full MOA and safety profile from DrugBank (DG001, DG002 data gaps must be resolved)
In vitro selectivity studies: determine IC₅₀ against P. falciparum versus host erythrocyte/hepatocyte toxicity to establish a preliminary therapeutic index
Rodent malaria model (e.g., P. berghei) proof-of-concept study to confirm in vivo efficacy and tolerability
Pharmacokinetic modelling to assess whether oral Colchicine achieves adequate parasite-inhibiting concentrations in blood without systemic toxicity
Comparative assessment against current first-line antimalarials (artemisinin-based combination therapies) to define potential niche (e.g., transmission-blocking via gametocyte inhibition)
Singapore regulatory pathway assessment if preclinical data becomes supportive (note: currently not registered with HSA)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.